Novelmed Therapeutics Announces Regulatory Clearance For Subcutaneous Ruxoprubart And Reports Positive Phase II Intravenous Monotherapy Results In PNH

(MENAFN - GlobeNewsWire - Nasdaq) --- Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration Key Highlights: ...